Results 231 to 240 of about 17,373,161 (316)
This study reveals that Urolithin A (UA) counteracts alcohol‐induced cognitive and social dysfunction (AICSD) via a gut microbiome‐dependent mechanism. UA‐enriched Bacteroids sartorii and Parabacteroids distasonis elevate anandamide (AEA), which activates the CB1R‐DRD2‐Rap1 signaling cascade to drive synaptic repair and reduce neuroinflammation ...
Hongbo Zhang +9 more
wiley +1 more source
Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. [PDF]
Zhang Z, Cui D, Wang H, Wu L, Liu X.
europepmc +1 more source
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source
The Current Landscape of Modular CAR T Cells. [PDF]
Joechner AH, Mach M, Li Z.
europepmc +1 more source
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang +15 more
wiley +1 more source
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma. [PDF]
Tu C +9 more
europepmc +1 more source
This study shows anti‐CEACAM5 CAR T‐cells are ineffective against colorectal cancer (CRC) because of CEACAM5 sequestration at intercellular junctions and the thick tumour cell glycocalyx. Enzymatic treatments of CRC cell monolayer/tissue section with trypsin or hyaluronidase restore CEACAM5 availability, enhance CAR T‐cell activation, increase ...
Debasis Banik +13 more
wiley +1 more source
CAR-engineered cell therapies: current understandings and future perspectives. [PDF]
Bayat M, Nahand JS.
europepmc +1 more source

